Purpose The use of novel and often expensive drugs offering limited survival benefit in advanced disease is controversial. Treatment recommendations are influenced by patient characteristics and trial data showing overall response rates (ORR), progression-free survival (PFS) and overall survival (OS). PFS is frequently the primary outcome in licencing studies. Patients and methods As part of a longitudinal study Assessing the 'VALue' to patients of PROgression Free Survival (AVALPROFS), oncologists completed checklists at baseline following consultations with patients. Questions probed perceived clinical benefits of the drugs to populations in general. Patients completed study-specific interview schedules at baseline, 6 weeks into treatment, and at withdrawal due to toxicity or progression. Patients also completed tumourand treatment-specific quality of life questionnaires monthly for their time in the study. Only baseline results are reported here. Results Thirty-two UK oncologists discussed management options with 90 patients with heterogeneous advanced cancers. Oncologists' estimates of medical benefit in general from treatment varied between 10 and 80 %. They expected 46/90 (51 %) of their patients to derive some clinical benefit from the prescribed treatment but were either unsure or expected none for 44/90 (49 %). Predictions of life expectancy were variable but 62 % (56/90) of patients were expected to survive longer with treatment. A majority of patients 51/90 (57 %) had 'no idea' or were 'unclear' what PFS meant and 45/90 (50 %) thought extension of life was the primary therapeutic aim of treatment. Conclusion Discussions between doctors and patients with metastatic disease about future management plans and likely therapeutic gains are challenging. Factors influencing decisions about putative benefits of novel drugs are often applied inconsistently can be overly optimistic and may even contradict published data.
Introduction
Progression-free survival (PFS) does not directly measure how patients feel, function or survive, but is increasingly used as a primary end point in clinical trials of solid tumour oncology therapy and by default for licencing and marketing approval [1] . PFS is described by the National Cancer Institute as 'the length of time during and after treatment for a disease such as cancer that a patient lives with the disease but it does not get worse' [2] . Although PFS is an attractive end point for a variety of practical, methodological and financial reasons, it does not always result in overall survival (OS). [3, 4] .
There is debate as to whether or not, for a patient, a longer PFS results in discernible and meaningful clinical benefit, the main goal of palliative anti-cancer treatment. Establishing PFS depends on RECIST (Response Evaluation Criteria in Solid Electronic supplementary material The online version of this article (doi:10.1007/s00520-016-3408-7) contains supplementary material, which is available to authorized users.
Tumours) criteria, which were developed to ensure some standardisation in the interpretation of drug activity on the tumour(s) in terms of stable disease, partial response or progression. The percentage increases or decreases in size shown on imaging and used by trialists were never intended to imply improvements or a decline in a patient's overall well-being. In the past decade, there has been a gradual increase in the number of publications from RCTs in common solid tumours where the primary end points have shifted from OS to PFS or time to progression. New 'fast-tracked' drug approvals are based increasingly upon surrogate end points with an expectation that post-marketing studies will later demonstrate other benefits such as OS. Completion of such studies is patchy and can demonstrate that PFS is not necessarily a reliable surrogate for OS [4, 5] .
There are few data demonstrating that stabilisation of metastatic disease and/or a reduction in the burden of disease symptoms are really worth any adverse treatment-related side effects from a patient's perspective [6, 7] . Addressing this question directly is hard as studies often either omit the inclusion of well-validated and relevant patient-reported outcome (PRO) measures altogether or rely instead on physicianreported CTCAE grades. Not only are these assessments fallible with little evidence of validity and dubious inter-rater reliability but they also fail to capture important information that might influence decision-making [8, 9] . Rarely have studies examined whether or not patients even understand the meaning of concepts such as PFS [10] .
Several reports show that patients with metastatic cancer need considerable help assimilating information about their disease and treatment goals; many have unrealistic perceptions of prognoses and the therapeutic intent of treatment which impacts decision -making [11] [12] [13] . Discussing management options with patients with advanced cancer is challenging as there is not always a sufficient and comprehensive evidence base for doctors to be realistic in their presentation of benefits and harms [14] and there is a tendency for oncologists to overestimate survival for terminally ill patients [15] .
This report focusses on oncologists' views about the likely and estimated benefits of the treatment regimens they were offering to patients, together with individual patients' understanding of therapeutic aims and expectations of treatment.
Methods-materials
Study design and participants AVALPROFS (Assessing the 'VALue' to patients of PROgression Free Survival) is a prospective, longitudinal study examining the value that patients with advanced disease place on the drugs they are receiving that control the cancer, compared to the treatment-related side effects. Patients, aware of their diagnoses, who were about to commence drug treatment, which at the time of enrolment had shown only PFS or modest OS gains, were invited to participate. Researchers presented the study to interested cancer teams in the UK. Oncologists then contacted the chief investigator to enrol in the study. AVALPROFS was approved by London-Surrey Borders Research Ethics Committee (Ref: 14/LO/0045).
Eligibility criteria
& Oncologists who prescribed drugs which at the time the study commenced had demonstrated only PFS or modest (1-3 months) OS benefits & Patients able to be interviewed in English, diagnosed with metastatic cancer and a predicted life expectancy of at least 6 months, prescribed drugs as described above
Procedures and measures
Potential patient participants were recruited between March 2014 and July 2015 from 11 cancer centres by their oncologists. Following the clinical consultation, patients who fulfilled the eligibility criteria for AVALPROFS were informed briefly about the study, given a patient information sheet to take home and an expression of interest form (EOI) to complete if they wanted to learn more. Patients provided their contact details on the EOI form, and a researcher telephoned 24 h later to explain the study in more detail.
Oncologists
Immediately following the consultations, during which management options were discussed with patients, oncologists completed checklists probing the information that they had provided. A similar checklist had been used previously to gather data examining information given to patients with advanced disease embarking on phase 1 trials [12] . This post consultation AVALPROFS checklist (shown in Appendix A) established the patient's diagnosis, stage and site of metastasis, treatments received to date and the drug discussed at the most recent consultation. Oncologists then indicated whether or not they had outlined certain areas of information including the aims of treatment using-'yes'/'no'/'can't recall'/'explained previously'-response options. They also estimated how much information they thought individual patients had understood.
In section 4 of the checklist, oncologists were asked what proportion of patients in general achieved some medical benefits from the drug and whether or not they expected each of their individual patients to derive any medical benefit. Response options were 'yes'/'no'/'don't know'. Finally, oncologists estimated the life expectancy of individual patients with and then without further treatment.
Patients
Participants were interviewed in their own homes (or by telephone if they preferred) by experienced researchers (LF, VJ, SC, VS) at baseline (within 2 weeks of the consultation) and again after 6 weeks of treatment. Further interviews were conducted at progression or if treatment was stopped due to toxicity. Patients stated the aims of treatment as they understood them and described any side effects experienced. They were also asked to make 'time trade-off' (TTO)-type assessments as to how worthwhile treatment would be or was, with different grades of side effect against the time that the treatment might control the cancer.
Participants also completed tumour-and treatment-specific quality of life questionnaires monthly up to 6 months. Written consent was obtained prior to the initial interview, which took place within 2 weeks from the consultation with the doctor.
This report focusses only on data collected at baseline from the oncologists' checklists and from participants' first interviews. We compared oncologists' views as to what was discussed in consultations with their patients' interpretations of that information. Topic areas included results from recent tests or scans, therapeutic aims of the drug discussed, side effects, whether or not the doctor used or explained the term PFS and patients' understanding of that concept.
Unlike the more usual time trade-off studies that probe hypothetical issues at one time point, this was a contemporaneous longitudinal observational study using real patients. Frequency counts and comparisons between responses were analysed using chi 2 statistical tests. Further analyses from the second and subsequent patient interviews, together with the health-related quality of life outcomes, will be reported separately.
Results
Thirty-two oncologists (16 men, 16 women) participated. Twenty-six were consultants, 3 specialist registrars and 3 senior fellows. Unfortunately, as the consort diagram (Fig. 1) shows, although 139 patients were approached, only 90 were interviewed, half of whom died or became too ill to continue through to the 6-month follow-up.
Demographics of the patients are shown in Table 1 . Two patients received treatment within a clinical trial. Oncologists reported that treatments being offered had already been mentioned in previous consultations with 59/90 (66 %) patients. Table 2 shows the topics oncologists thought that they had explained or discussed during individual patient consultations. The majority (80/90; 89 %) felt that they had checked their patients' comprehension about the information given and 74/ 90 (82 %) thought that their patients had fully or mostly understood the discussion. A majority of patients (87/90; 97 %) reported receiving additional information leaflets about the treatments that they were starting.
Oncologists' expectations of medical benefit
Oncologists expected that 46/90 (51 %) of their patients would derive some medical benefit, and were unsure (39/90; 43 %) or expected no benefit for others (5/90; 6 %), all of whom nevertheless were prescribed treatments. Quotes from oncologists are shown below.
I explained to patient that the drug may work well and slow progression and re-accumulation of pleural effusion, but also that it may not work (everolimus & exemestane).
This disease has behaved unusually so far so difficult to predict (cetuximab + cisplatin).
No way of being sure as no biomarker (sunitinib). The responses to questions regarding putative medical benefits of treatments were inconsistent. For example in response to the question 'What percentage of patients do you think will
Approached n=139
Eligible for study n=120 (EOI received)
Consented to study n=93
Declined study n=27
Ineligible n=19
• Too ill =8
• Drug not suitable =5
• InpaƟent =3
• Could not speak English =1
• On placebo trial =1
• Already been on drug too long =1
Baseline n=90
Excluded n=3
• Drug not suitable =2
• PaƟent withdrew consent =1 (30) afatinib (1) carboplatin + etoposide (1) or gemcitabine (1) pemetrexed + carboplatin (2) or cisplatin (2) erlotinib (23) Melanoma (19) ipilimumab (15) dabrafenib (2) vemurafenib (2) Breast (18) bevacizumab + paclitaxel (2) eribulin (6) everolimus (1) + exemestane (4) TDM-1 (2) pertuzumab + docetaxel + trastuzumab (3) Renal (10) sunitinib (5) pazopanib (2) axitinib (2) everolimus (1) Gynae (7) bevacizumab (2) + carboplatin + paclitaxel (4) or + gemcitabine (1) Head & Neck (3) cetuximab + cisplatin (2) cetuximab + carboplatin +5FU (1) Colorectal (2) bevacizumab (1) bevacizumab + capecitabine (1) Sarcoma (1) pazopanib ( Oncologists' expectations of patients' survival with and without treatment
Two of the 90 patients who completed baseline assessments were too ill to even start treatment and 18/84 (21 %) died within 6 months of study entry. The mean survival time for 14/18 patients for whom the oncologists had shifted survival expectations with treatment in an optimistic direction was 89 days (sd. 41, min-max 25-177 days). Table 3 shows estimates of life expectancy without and then with treatment for lung cancer patients (who formed the largest tumour group) and for all other patients. It can be seen that oncologists estimated no change in life expectancy for 34 patients receiving treatments, and an optimistic shift for the other 56 patients.
Only 46/90 (51 %) of oncologists had discussed other supportive care plans with patients.
Patient-reported cancer symptoms
Two thirds of patients reported one or more symptoms that they attributed to their cancer at baseline. The five most common were pain (33/90, 37 %), breathlessness (30/90, 33 %), fatigue (23/90, 26 %), cough (13/90, 14 %) and loss of appetite (7/90, 8 %).
Side effects from treatment
Twenty-five percent of patients had not started treatment at the time of the first interview, and 68/90 (75 %) had received fewer than 2 weeks of treatment, yet 43/68 (63 %) were experiencing side effects. These were skin rash (11/43; 26 %), fatigue (9/43; 21 %), nausea (9/43; 21 %), diarrhoea (9/43; 21 %), mouth sores (5/43; 12 %) and breathlessness (1/43; 2 %). The worst side effects most often anticipated by patients who had not commenced treatment (22/90), or had Expectation of a longer life as a treatment benefit was not influenced by age (older or younger than 65 years), sex, cancer symptoms, previous chemotherapy treatment or tumour type. Table 4 shows the responses to the time trade-off questions at baseline. The top four side effects nominated by patients and used for these questions were nausea (21/90; 23 %), diarrhoea (20/90; 22 %), fatigue (14/90; 16 %) and breathlessness (13/ 90; 14 %). As the possible severity of the side effect increased, patients were significantly less inclined to feel that the benefit of controlling the cancer would be worthwhile (X 2 = 75.6004; p < 0.00001). There was also an increase in the amount of time that patients would require the drug to control the cancer, for it to be considered a worthwhile treatment.
Time trade-off questions

Discussion
Results from this study showed that oncologists' general estimates of the likely therapeutic gains achievable from new treatments are sometimes at odds with available trial data and were inconsistent between individual patients. Some oncologists' expectations regarding likely treatment benefits especially survival times were difficult to understand and we would assume therefore they were influenced by criteria other than published data. These may include anecdotal experience, personal bias or belief that the patient's cancer represents a particular and preferential subset within the disease spectrum. The patients in this study were all considered suitable for treatment by their oncologists, but some were outside the limited eligibility criteria of trials. Oncologists may therefore have believed that the trial data (population) were not directly comparable to their patient's disease (individual). In some relatively rare cases, published trial data lags behind later evidence of improvement which may have influenced oncologists in AVALPROFS who were recruiting patients to other relevant studies (e.g. with the melanoma drug ipilimumab or pertuzumab in breast cancer) [16] [17] [18] .
In AVALPROFS a heterogeneous group of patients were studied but lung cancer formed the largest group. Targeted agents were prescribed for 24 patients with lung cancer, only 13 of whom had an EGFR mutation. This finding is not unusual and corroborates results of a recent survey of 562 oncologists in 10 countries, showing that one in four patients with advanced lung cancer did not have EGFR-TK test results available before starting targeted treatment [19] . For those patients who were EGFR-TK+, oncologists estimated benefits from treatment that ranged from 20 to 80 % of patients in general; suggesting widely differing views. Moreover, where patients identified as wild type were prescribed EGFR-TK inhibitors, the oncologists' estimates of the percentage of patients in general likely to benefit from such treatment varied, between 10 and 40 %, which is greater than the published trial evidence [20] . Additionally, we found oncologists had expectations that patients having erlotinib would live longer. These data highlight incongruities and perhaps interplay of optimism. Drugs like erlotinib, vemurafenib and afatanib that target specific pathways have biomarkers (identifiable gene mutations) to help indicate usage, but other novel treatments such as ipilimumab work via different means and currently have no biomarker guidance, increasing the area of uncertainty for oncologists and their patients [16, 20, 21] . Neither NICE nor the manufacturers of drugs such as erlotinib recommend their use as treatment in end-of-life circumstances. [22, 23] . A significant minority (21 %) of patients died within 6 months of entering AVALPROFS, with an average OS of 89 days (sd. 41). These findings are consistent with results from a retrospective study of 816 advanced cancer patients who had received targeted agents within the last 30 days of their lives. (The population studied in this report were mainly younger patients with haematological malignancies and those with lung cancer) [24] . Undue optimism about survival prospects held by oncologists may contribute to their prescribing habits, combined with a very real difficulty in having the honest and sometimes distressing discussions about prognosis. It has been shown that cancer patients with advanced disease who themselves hold overly optimistic assessments of their own survival often request active treatments rather than perhaps more beneficial supportive care [10] .
Doctor-patient communications at these important decision points are further complicated by confusing medical terminology; healthcare professional jargon is often meaningless or misunderstood by the patient. It is perhaps not surprising that the phrase PFS was rarely used in consultations and when asked, most patients were unclear of its meaning. However, this does not explain why a majority of patients in the study thought that slowing or stopping the cancer growing, would then translate into them living longer. PFS is a confusing term and the word 'survival' implied to some patients that the primary aim and likely benefit was to extend life. Progression-free interval might be a more helpful phrase to use when discussing drugs with PFS or modest OS benefits.
Agreement about what constitutes clinically meaningful benefit remains controversial even with the relatively robust endpoint of OS [25] . The benefits achievable from targeted treatments, especially patient-reported side effects and quality of life are vital if treatment effects are to be determined comprehensively [26] . In this study, side effects occurred within 2 weeks of starting treatment and from the patients' perspective, the worst were nausea and diarrhoea. Despite this, the vast majority believed the benefit of the drug in terms of controlling the cancer was worth grade I (95 %) and grade II (88 %) side effects, but dropped to 44 % at grade III. Discussions with patients about disease progression and communicating the benefits of further active treatment in the palliative setting are challenging and nuanced so there is a need to balance many factors. It is essential for oncologists to retain perspective on what constitutes a meaningful benefit to patients, namely one that will bring improvements in symptoms and/or quality of life not just arrest of tumour burden on imaging or reductions in tumour markers.
